Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.
Advertisement

Related Content

Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says
Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel